Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Websites

  • OxPPL

    Oxford Precision Psychiatry Lab

  • OH-CRF

    NIHR Oxford Health Clinical Research Facility

Caroline Zangani

MD, Psychiatrist

RESEARCHER

 

  • Researcher, Oxford Precision Psychiatry Lab (OxPPL), Department of Psychiatry, University of Oxford.
  • GRADUATE reading for Doctor of Medicine, Medical Science Division, University of Oxford.
  • Specialty Doctor in Clinical Research, NIHR Oxford Health Clinical Research Facility (OH-CRF), Oxford Health NHS Foundation Trust, Oxford

 

As a member of the OxPPL, my main research focus is evidence-based synthesis and personalised medicine. My research is focused on solving real-world clinical challenges and enhancing everyday practice. I have recently started a Doctor of Medicine (DM) degree (a PhD-equivalent part-time doctoral programme, open to doctors employed in the NHS locally or by the University) focusing on identifying and targeting specific dimensions of clinical symptoms in major depressive disorder. 

As part of it, I am working on an Individual Participant Data-Network Meta-Analysis (IPD-NMA) on the efficacy of common antidepressants on depressive dimensions (https://osf.io/n4jea/?view_only=312cbd9513044b66a5c44682fbcd8429). The main aim of this project is to characterise the effect of different antidepressants on specific clusters of depressive symptoms, which better resemble the clinical presentations of depression encountered during clinical practice. This will help patients and clinicians find the most suitable treatment based on their unique symptomatology profile, distancing the treatment choice from the old one-size-fits-all concept.

My clinical work at the OH-CRF includes setting up and delivering high-intensity, experimental trials in individuals with cognitive and mental health conditions. I routinely liaise with university staff, commercial sponsors, and third-party vendors to conduct study activities safely and efficiently. My daily tasks range from completing clinical assessments and psychiatric interviews to preparing and administering investigational medicine products in oral, intravenous, or other formulations.

I am the Oxford-site Principal Investigator (PI) for the EULAST II trial (NCT05165316), a multi-centre follow-up cohort study aiming to investigate the long-term outcomes of patients with schizophrenia who participated in the previously conducted EULAST-I clinical trial, in the first decade after being diagnosed.